Sermorelin Peptide

Product Specifications

CAS: 86168-78-7

Also Known As: Sermorelin Acetate, GHRH(1-29)-NH₂, GRF(1-29)

Sequence: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂

Molecular Formula: C₁₄₉H₂₄₆N₄₄O₄₂S

Molecular Weight: 3357.9 Da

Purity: 99%+ (verified by HPLC)

Appearance: White to off-white lyophilized powder

Form: Lyophilized (freeze-dried)

Classification: GHRH Analogue (Synthetic GHRH Fragment, Residues 1-29)

Half-life: Approximately 10-20 minutes (reflects native GHRH(1-29) sequence without stabilizing substitutions)

Storage

Sermorelin vials must be stored in a cool, dry place away from direct sunlight. Unreconstituted sermorelin peptide should be kept at -20°C for long-term storage or 2-8°C for short-term use. Does sermorelin need to be refrigerated? Once reconstituted with bacteriostatic water, sermorelin must be stored at 2-8°C and used within 28-30 days. Do not freeze reconstituted solutions.

Solubility

Sermorelin is freely soluble in bacteriostatic water and sterile saline. Gently swirl the vial after adding solvent. Do not vortex or shake vigorously.

Intended Use

Sermorelin is intended for research purposes only and is not approved for human use.

What Is Sermorelin? GHRH Receptor Activation and Pulsatile GH Release

• Sermorelin is a 29-amino acid synthetic peptide corresponding to the biologically active N-terminal fragment of endogenous GHRH. It binds to and activates the GHRH receptor (GHRHR) on pituitary somatotrophs with the same receptor affinity as full-length GHRH, triggering the synthesis and pulsatile release of growth hormone in a pattern that closely mirrors the body's natural secretory rhythm.
• What does sermorelin do at the cellular level: GHRHR activation by sermorelin increases intracellular cAMP via adenylyl cyclase signalling, stimulating both the immediate release of stored GH from secretory granules and the transcription of the GH gene for sustained production. Each administration produces a discrete, short-duration GH pulse reflecting sermorelin's 10-20 minute plasma half-life.
• Sermorelin side effects in preclinical research are consistent with GHRH receptor activation and are generally mild, primarily involving transient injection site reactions and dose-dependent increases in GH and IGF-1. Sermorelin long-term side effects in preclinical models show no significant adverse findings at standard research doses. Sermorelin side effects and cancer: preclinical research has not identified a carcinogenic mechanism at physiological stimulatory doses in published animal studies.
• Is sermorelin safe? Preclinical studies across multiple animal models show a well-tolerated profile at research doses, with no significant off-target receptor activation outside the GHRH signalling pathway. The peptide is highly specific for the GHRHR, which limits systemic off-target effects compared to compounds that activate multiple receptor classes.

Sermorelin Benefits for Muscle Growth, Body Composition, and Weight Loss

• Sermorelin peptide benefits for body composition operate through the GH/IGF-1 axis: sermorelin-stimulated GH pulses drive hepatic IGF-1 production, which in turn activates anabolic signalling in skeletal muscle (PI3K/Akt/mTOR pathway) and promotes lipolysis in adipose tissue. Research demonstrates that pulsatile GH stimulation supports lean mass preservation and fat reduction in animal models.
• Sermorelin dosage for muscle growth in animal research is linked to the amplitude and frequency of GH pulses generated. Studies show that more frequent administration can increase total daily GH output and correspondingly elevate circulating IGF-1, the primary downstream mediator of sermorelin's anabolic effects on skeletal muscle and bone.
• Sermorelin for weight loss and sermorelin weight loss research in preclinical models identifies GH-driven lipolysis as the primary mechanism, with elevated GH promoting free fatty acid mobilisation from adipocytes and shifting substrate utilisation toward fat oxidation. Sermorelin before and after body composition studies in animal models show measurable reductions in fat mass over sustained research periods of 4-12 weeks.
• Sermorelin benefits for males and females in preclinical models are consistent: GH/IGF-1 axis stimulation drives lean mass support, fat metabolism, and connective tissue maintenance across sexes. Sermorelin before and after face and skin research in animal models reflects GH's known role in collagen synthesis and dermal thickness maintenance.

Sermorelin vs Ipamorelin, CJC 1295, and Tesamorelin

• Sermorelin vs ipamorelin: sermorelin acts on the GHRH receptor (GHRHR) via the cAMP pathway, while ipamorelin acts on the GHS-R (ghrelin receptor) via the phospholipase C/calcium pathway. Both stimulate GH release through different receptor targets. Combined sermorelin and ipamorelin administration produces a synergistic GH pulse greater than either compound alone, as the two pathways converge on GH secretion from pituitary somatotrophs.
• Sermorelin vs CJC 1295: sermorelin matches the native GHRH(1-29) amino acid sequence without the four stabilising substitutions found in CJC 1295 (Modified GRF 1-29). CJC 1295 has a longer active half-life (approximately 30 minutes vs 10-20 minutes for sermorelin) due to greater DPP-4 resistance, producing a somewhat more sustained GH pulse per administration. Both activate the same GHRHR receptor.
• Tesamorelin vs sermorelin: tesamorelin is a synthetic GHRH analogue that includes the full 44-amino acid GHRH sequence with a trans-3-hexenoic acid modification at the N-terminus that confers greater stability. Tesamorelin has a longer half-life than sermorelin and has been studied for its effects on visceral adipose tissue reduction in animal models of metabolic dysfunction, representing a distinct research profile from sermorelin's shorter-duration GH pulse approach.
• Sermorelin vs HGH: where exogenous growth hormone directly replaces endogenous GH, sermorelin works upstream by stimulating the pituitary to produce GH through its natural receptor pathway. Research interest in sermorelin reflects the scientific value of studying physiological GH pulse stimulation as distinct from continuous exogenous GH administration.

Sermorelin Dosage for Research

Sermorelin dosing in preclinical research reflects its short plasma half-life of 10-20 minutes, requiring more frequent administration compared to longer-acting GHRH analogues. Sermorelin dosage protocols in published literature include:

• Subcutaneous injection: 1-10 mcg/kg body weight, once to twice daily in rodent models. Sermorelin dosage for muscle growth research typically uses the higher end of this range with daily administration to maximise cumulative GH pulse output.
• Sermorelin and ipamorelin combination: Matched concentrations of both peptides, administered together once or twice daily to leverage synergistic GH release. Sermorelin-ipamorelin-CJC 1295 triple combinations are also studied in GH secretion research.
• Sermorelin dosage for bodybuilding research: Studies examining lean mass and body composition endpoints typically use 2-4 mcg/kg once or twice daily in rodent models, timed before rest or fasted states to align with natural GH secretion windows.

Sermorelin dosage chart comparisons across published studies show dose-dependent GH responses with diminishing returns at higher doses due to receptor saturation. How long does it take for sermorelin to work: GH pulse elevation is detectable within 15-30 minutes of administration in animal models, while body composition endpoints require 4-12 weeks of consistent dosing to show statistically significant changes. Sermorelin dosage in ml is determined by the reconstitution volume and target dose per kilogram, which varies by study design.

Research Protocol Notes

Sermorelin is supplied as a lyophilized (freeze-dried) powder. For research use, the peptide must be reconstituted with bacteriostatic water or sterile saline. Introduce the solvent slowly down the inside wall of the vial and gently swirl to dissolve. Do not shake or vortex. Where to inject sermorelin in research protocols: standard subcutaneous sites include the abdomen or dorsal flank in animal models, with sermorelin injection sites rotated between administrations. Does sermorelin need to be refrigerated? Reconstituted sermorelin must be stored at 2-8°C and used within 28-30 days. Unreconstituted sermorelin peptide should be kept at -20°C for long-term stability. What happens when you stop taking sermorelin in research contexts: GH pulse amplitude returns to baseline levels as the stimulatory effect of each administration resolves within the compound's short half-life window.